copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Frontline treatment options for higher-risk MDS: can we move . . . FUSION-AML-001 (MDS Cohort) 2 azacitidine + durvalumab (1500 mg IV q 4 weeks) azacitidine Int to very high MDS IPSS-R int to very high ORR (CR, mCR, HI) 61 9% vs 47 6% (P = 0 18) No Increase PDL1 on BM Blasts 29 SUPPORT 3 azacitidine + eltrombopag (200 mg day, up to 300 mg day) azacitidine Int to HR-MDS
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS We analyzed data from adult patients with low- or intermediate-1–risk MDS or chronic myelomonocytic leukemia, as measured by the International Prognostic Scoring System, who had been enrolled in a randomized phase 2 study of low-dose decitabine versus low-dose azacitidine; the description of trial methods and results with follow-up of x-years has been previously published 8 Briefly
Successful long-term treatment with azacitidine in patient . . . Several studies and clinical trials tested efficacy of both azacitidine and decitabine and they revealed overall response rates in the range of 30-60% and a median Overall Survival (OS) between 12 to 37 months 3,4,11,12 Based on latest findings, azacitidine was licensed for non-proliferative CMML-2, whereas there are limited data for
Efficacy of azacitidine is independent of molecular and . . . Azacitidine is the first drug to demonstrate a survival benefit for patients with MDS However, only half of patients respond and almost all patients eventually relapse Limited and conflicting data are available on predictive factors influencing response We analyzed 128 patients from two instituti …
5-azacitidine prolongs overall survival in patients with . . . In a number of phase 2 trials 5-azacitidine and decitabine given to patients with MDS resulted in an overall response rate of 50% 5 – 8 This led to the initiation of phase 3 trials comparing 5-azacitidine or decitabine to best supportive care
Combination Therapy Shows Promising Results in Some Higher . . . “All the signals of activity go in the same direction, which is always encouraging with a drug,” Dr Sekeres says Efficacy results were strongest in the higher-risk MDS group, with a significant improvement in event-free survival among the cohort receiving the combination therapy compared with azacitidine alone (20 2 months vs 14 8 months), and in overall survival (23 9 months vs 19 1
Vidaza® Improves Survival in Myelodysplastic Syndromes Vidaza was the first agent approved for the treatment of MDS in 2004 It applies its anticancer effects by targeting aspects of expression of DNA, ultimately killing cancer cells Vidaza has demonstrated the ability to reduce or prevent the need for blood transfusions in MDS; however, its effects on survival have not been clearly established